Pregledni rad
Immunotherapy of renal cell carcinoma
Marija Miletić
; Clinical Department of Oncology and Nuclear Medicine,Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Marijana Jazvić
; Clinical Department of Oncology and Nuclear Medicine,Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Jasna Radić
; Clinical Department of Oncology and Nuclear Medicine,Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Marin Prpić
; Clinical Department of Oncology and Nuclear Medicine,Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Blanka Jakšić
; Clinical Department of Oncology and Nuclear Medicine,Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ante Bolanča
; Clinical Department of Oncology and Nuclear Medicine,Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Denatal medicine, University of Zagreb, Zagreb, Croatia
Sažetak
Targeted therapy has been the standard of care for the treatment of metastatic renal cell carcinoma (mRCC). The current standard of care focuses on tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib), antibodies to circulating VEGF receptor (bevacizumab) and m-TOR inhibitors (temsirolimus, everolimus). New immune-based therapies are emerging as a promising treatment for mRCC. Immune checkpoint blockade has shown clinically signifi cant antitumor response. Monoclonal antibodies against immune checkpoint blockade molecules including PD-1 (programmed cell death 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) have become a major focus in the immune-based therapy since it has been reported that they have impressive antitumor eff ects.
The most studied inhibitors in the PD-1 pathway are: nivolumab, pembrolizumab and atezolizumab. Based on the results of the phase III clinical trial (CheckMate025) nivolumab, humanized monoclonal IgG4 antibody against PD-1, is the only agent that is approved by the FDA for the second-line treatment of mRCC. Ipilimumab is the fi rst-in-class immunotherapeutic for blockade of CTLA-4. The immunotherapy combinations have demonstrated promising results in a randomized
trials. The use of cancer treatment vaccines is another approach to immunotherapy and will be systematically evaluated in the future.
Immunotherapy has demonstrated great clinical potential and it represents crucial component of mRCC treatment. Developing immunotherapy to the point of clinical utility presents a number of issue and challenges, and more rigorous studies are needed.
Ključne riječi
renal cell carcinoma; immunotherapy; checkpoint inhibition; vaccines
Hrčak ID:
192134
URI
Datum izdavanja:
21.12.2017.
Posjeta: 2.850 *